| 1 |
中国高血压防治指南修订委员会. 中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
|
| 2 |
Chobanian AV, Bakris GL,Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure: the JNC 7 report [J].JAMA,2003,289(19):2560-2572.
|
| 3 |
Kjeldsen SE, Erdine S, Farsang C, et al. 1999 WHO/ISH Hypertension Guidelines-highlights & ESH Update [J]. Blood Press,2003,12(3):181-182.
|
| 4 |
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens,2013,31(7):1281-1357.
|
| 5 |
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [J]. Am J Kidney Dis, 2004, 43(5 Suppl 1): S1-S290.
|
| 6 |
Kidney Disease: Improving Global Outcomes ( KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J].Kidney Int,2012,2(Suppl 5):337-414.
|
| 7 |
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC8) [J]. JAMA,2014,311(5):507-520.
|
| 8 |
Padwal RS, Hemmelgarn BR, Khan NA, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1-blood pressure measurement,diagnosis and assessment of risk [J]. Can J Cardiol,2008,24(6):455-463.
|
| 9 |
Yuan-Nan Ke, Yu-Gang Dong, Shu-Ping Ma, et al. Improved blood pressure control with nifedipine GITS/Valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial [J]. Cardiovasc Ther,2012,30(6):326-332.
|
| 10 |
Ruilope LM, Kirwan BA, de Brouwer S, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial:impact of nifedipine GITS(gastrointestinal therapeutic system) and relation to outcome [J]. J Hypertens,2007,25(8):1711-1718.
|
| 11 |
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients [J]. N Engl J Med,2008,359(23):2417-2428.
|
| 12 |
Kanaoka T, Tamura K, Wakui H, et al. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease [J]. Int J Mol Sci,2013,14(8):16866-16881.
|
| 13 |
Tomino Y, Shimizu Y, Hamada C, et al. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease [J]. J Nephrol,2011,24(6):756-763.
|
| 14 |
Nakamura T, Sato E, Fujiwara N, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FAB P, and inflammatory and atherosclerosis markers in earlystage chronic kidney disease [J]. Am J Med Sci, 2010, 339(2):157-163.
|
| 15 |
Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria[J]. Hypertens Res,2011,34(2):268-273.
|
| 16 |
Yamamoto E, Kataoka K, Dong YF, et al. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats [J]. J Hypertens,2010,28(6):1321-1329.
|
| 17 |
Swan SK, Olyaei A, Sica D. Clinical pharmacology for the nephrologist [J]. Nephrol Self Assess Program,2010,9:220-264.
|